Epidemiology of heart failure with preserved ejection fraction: Results from the RICA Registry

Pérez-Calvo, Juan Ignacio; Iborra, Pau Llàcer; Pedreira, Iván Suárez; Rangel, Llanos Soler; Franco, Álvaro González; Cansino, D. Adarraga; Rocha, Pablo Álvarez; Arévalo‐Lorido, J.C.; Carrascosa, S.; Cepeda, José María; Conde‐Martel, Alicia; Escrivá, Dolores; Acuña, A. León; Llàcer, Pau; Montero-Pérez-Barquero, Manuel; Palanco, Miguel Ángel Moreno; Ormaechea, Gabriela; Calvo, Juan; Suarez, Soraya; Nino, Jessica; Rangel, M.L. Soler; Trullàs, Joan Carles; Ronda, Maité Ávila

doi:10.1016/j.medcle.2020.05.045

Cited by 5 publications

(5 citation statements)

References 35 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…But does this entity exist? The bimodal distribution of the LVEF that we found in our work and described in other studies would be in favour of 2 subtypes of heart failure and not 3 [16]. Then, HFmrEF appears closer to HFpEF in our work as in that of Koh et al [27].…”

Section: Discussionsupporting

confidence: 79%

“…This entity has several phenotypes [15]. Western epidemiological data report a high prevalence of HFpEF exceeding 50% in some studies compared to 17.6% in our study [15,16]. However, these results are to be qualified, most studies using only the LVEF as diagnostic criteria without sometimes excluding HFmrEF and often heart diseases which do not come under the new diagnostic criteria.…”

Section: Discussioncontrasting

confidence: 62%

See 1 more Smart Citation

Clinical Profiles and One-Year Prognosis of Heart Failure in a Sub-Saharan Country of Africa

Adoubi¹,

Soya²,

Diby³

et al. 2022

JICOA

View full text Add to dashboard Cite

Background: New classification of heart failure according to ejection fraction calls for exploring in black Africans. Objectives: To determine our patient's characteristics and prognosis of the subtypes of heart failure. Methods: We analysed data from consecutive black African patients hospitalised for heart failure at Heart Institute of Abidjan in 2018 and followed up for one year. Results: Were considered 251 heart failure patients (age: 55.5 ± 16.3 years, 63.7% of males) with preserved (HFpEF) (18.7%), mid-range (HFmrEF) (17.6%), and reduced ejection fraction (HFrEF) (63.7%). HFpEF patients were older (p <0.0001) and had more frequently. acute pulmonary oedema. From an echocardiographic point of view, HFpEF patients had, on average, a smaller left ventricle than the other patients (p <0.001), but a larger left atrium (p <0.05). Clinically, these patients were admitted more often with acute pulmonary oedema (p = 0.01) and had more often comorbidities (p=0.00)4. However, survival was better with HFpEF patients than HFrEF patients (log-rank = 4.61; p = 0.032). HFmrEF patients have an intermediate profile. Conclusion: In our context, although they have the same expression, HFrEF and HFPEF appear very different. We need further studies for a better understanding of HFmrEF.

show abstract

Section: Discussionsupporting

confidence: 79%

Section: Discussioncontrasting

confidence: 62%

Clinical Profiles and One-Year Prognosis of Heart Failure in a Sub-Saharan Country of Africa

Adoubi¹,

Soya²,

Diby³

et al. 2022

JICOA

View full text Add to dashboard Cite

show abstract

“…2020; Trullas et al. 2021). In China, according to the 2018 China Cardiovascular Report, the prevalence of CHF is about 0.9%, and the mortality rate is about 4.1%, which is equal to that of a malignant tumor.…”

Section: Introductionmentioning

confidence: 99%

“…Chronic heart failure (CHF) is a group of clinical syndromes caused by low ventricular filling and/or ejection capacity due to various cardiac structural or functional abnormalities, which is the terminal stage of the development of most cardiovascular diseases (Wang and Liang 2018). According to statistics, there are as many as 23 million patients with CHF worldwide and they increase at the rate of 2 million per year, among which the prevalence rate of the elderly over the age of 70 is as high as 10% (Morbach et al 2020;Trullas et al 2021). In China, according to the 2018 China Cardiovascular Report, the prevalence of CHF is about 0.9%, and the mortality rate is about 4.1%, which is equal to that of a malignant tumor.…”

Section: Introductionmentioning

confidence: 99%

Spiritual care needs among Chinese elders hospitalized for severe chronic heart failure: An observational study

et al. 2022

View full text Add to dashboard Cite

Objectives To investigate the spiritual care needs and their attributes among Chinese elders hospitalized for severe chronic heart failure (CHF) based on the Kano model, in order to provide a reference for improving the quality and satisfaction of spiritual care. Methods An observational design was implemented, and the STROBE Checklist was used to ensure quality reporting of the study. The demographic characteristics questionnaire, the Nurse Spiritual Therapeutics Scale, and the Kano model–based Nurse Spiritual Therapeutics Attributes Scale were used. A convenience sample of 451 patients were selected from 2 hospitals. Descriptive statistics, and Kano model were used to analyze the data. Results The total score of spiritual care needs was 29.95 ± 7.51. Among the 12 items, 3 items were attractive attributes, all of which were located in Reserving Zone IV; 5 items were one-dimensional attributes, of which 3 were located in Predominance Zone I and 2 were located in Improving Zone II; 2 items were must-be attributes, all of which were located in Improving Zone II; and 2 items were indifference attributes, all of which were located in Secondary Improving Zone III. Significance of results The spiritual care needs among Chinese elders hospitalized for severe CHF were moderate. The must-be and one-dimensional attributes mainly focus on “creating a good atmosphere” and “sharing self-perception” dimensions, while attractive attributes mainly focus on “sharing self-perception” and “helping thinking” dimensions. It is suggested that hospital authority should develop and innovate attractive attributes on the basis of maintaining and perfecting must-be and one-dimensional attributes, and objectively analyze and optimize indifference attributes.

show abstract

“… 1 Chronic HF can be categorized into two main phenotypes based on the left ventricular ejection fraction (LVEF): LVEF ≤ 40% [HF with reduced ejection fraction (HFrEF)] and LVEF > 40% (composed of HF with mildly reduced and preserved ejection fraction). 1 , 2 Of the total chronic HF population, the proportion of patients with LVEF > 40% range from 30% to 50% 3 , 4 , 5 ; however, the proportion can reach as high as 85% among elderly patients. 6 Regardless of the phenotype, patients with chronic HF experience acute episodes of worsening symptoms that may further impair the heart's ability to function, leading to increased disability and a heightened risk of death.…”

Section: Introductionmentioning

confidence: 99%

Multinational cost‐effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40%

Kolovos,

Bellanca,

Groyer

et al. 2023

ESC Heart Failure

View full text Add to dashboard Cite

AimsHeart failure is a chronic progressive condition, with considerable burden on patients' quality of life and economic burden for the healthcare systems. Before the approval of empagliflozin, there were no proven effective treatments for patients with heart failure with left ventricular ejection fraction (HF LVEF) > 40%. The aim of this study was to evaluate the cost‐effectiveness of empagliflozin + standard of care (SoC) compared with SoC alone for patients with HF LVEF > 40%, from the perspective of the healthcare systems of the United Kingdom (UK), Spain, and France, and to quantify the healthcare costs for these patients.Methods and resultsA lifetime Markov cohort state‐transition model was developed based on discrete health states defined by Kansas City Cardiomyopathy Questionnaire‐Clinical Summary Score quartiles to track disease severity. Model inputs relied primarily on the EMPEROR‐Preserved trial data or obtained from published literature or country‐specific databases, as well as local guidelines for the requirements for the conduct of the economic evaluation of healthcare technologies. The total lifetime cost of receiving SoC per patient was £10 092, €15 765, and €14 958 in the UK, Spain, and France, respectively, which increased by £1407, €1148, and €1485, respectively, with the addition of empagliflozin to the SoC. Empagliflozin + SoC was associated with significantly reduced number of hospitalization for HF or cardiovascular death compared with SoC alone, which was a key driver offsetting its drug acquisition costs. The incremental cost‐effectiveness ratio per quality‐adjusted life year (QALY) gained was consistently favourable at £14 851, €11 706, and €15 447 in the UK, Spain, and France, respectively. Scenario analysis using the New York Heart Association functional class showed similar results. Probabilistic sensitivity analyses showed more than 50% probability for cost‐effectiveness for a willingness‐to‐pay (WTP) threshold of £/€20 000/QALY for the three countries.ConclusionsEmpagliflozin was found to be the first targeted treatment option that is clinically effective and cost‐effective for patients with HF LVEF > 40%. Prescribing empagliflozin with SoC to patients with HF LVEF > 40% is expected to improve clinical outcomes and patients' quality of life and substantially below accepted WTP threshold for the healthcare systems in the UK, Spain, and France.

show abstract

Epidemiology of heart failure with preserved ejection fraction: Results from the RICA Registry

Cited by 5 publications

References 35 publications

Clinical Profiles and One-Year Prognosis of Heart Failure in a Sub-Saharan Country of Africa

Clinical Profiles and One-Year Prognosis of Heart Failure in a Sub-Saharan Country of Africa

Spiritual care needs among Chinese elders hospitalized for severe chronic heart failure: An observational study

Multinational cost‐effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40%

Contact Info

Product

Resources

About